Syneos Health, Inc. (SYNH)

NASDAQ: SYNH · IEX Real-Time Price · USD
47.15
-0.31 (-0.65%)
Sep 30, 2022 4:00 PM EDT - Market closed
-0.65%
Market Cap 4.84B
Revenue (ttm) 5.42B
Net Income (ttm) 278.12M
Shares Out 102.65M
EPS (ttm) 2.61
PE Ratio 18.07
Forward PE 8.90
Dividend n/a
Ex-Dividend Date n/a
Volume 739,526
Open 47.69
Previous Close 47.46
Day's Range 47.11 - 49.42
52-Week Range 46.24 - 104.18
Beta 1.75
Analysts Buy
Price Target 79.05 (+67.7%)
Earnings Date Nov 1, 2022

About SYNH

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, ... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Nov 7, 2014
CEO Alistair Macdonald
Employees 26,751
Stock Exchange NASDAQ
Ticker Symbol SYNH
Full Company Profile

Financial Performance

In 2021, Syneos Health's revenue was $5.21 billion, an increase of 18.05% compared to the previous year's $4.42 billion. Earnings were $234.83 million, an increase of 21.81%.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for SYNH stock is "Buy." The 12-month stock price forecast is 79.05, which is an increase of 67.66% from the latest price.

Price Target
$79.05
(67.66% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here's Why Investors Should Retain Syneos Health (SYNH) for Now

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.

2 weeks ago - Zacks Investment Research

Syneos Health to Present at the 2022 Baird Global Healthcare Conference

MORRISVILLE, N.C, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michell...

1 month ago - GlobeNewsWire

physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health to Accelerate Innovative Phase III Study i...

CHICAGO--(BUSINESS WIRE)-- #AI--A leader in continuous remote patient monitoring and data analytics, physIQ today announced a strategic collaboration with InCarda Therapeutics, Inc., a privately-held, c...

1 month ago - Business Wire

Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View

Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.

1 month ago - Zacks Investment Research

Syneos Health (SYNH) Beats Q2 Earnings Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.17% and 1.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Syneos Health Reports Second Quarter 2022 Results

MORRISVILLE, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today reported financial results for the three and s...

2 months ago - GlobeNewsWire

Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Syneos Health Schedules Second Quarter 2022 Earnings Call for Tuesday, August 2, 2022

MORRISVILLE, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2022 financial resu...

2 months ago - GlobeNewsWire

Syneos Health (SYNH) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

3 months ago - Zacks Investment Research

Here's Why Investors Should Retain Syneos Health (SYNH) For Now

Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.

3 months ago - Zacks Investment Research

Syneos Health to Present at Upcoming Investor Conferences

MORRISVILLE, N.C., May 24, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present a...

4 months ago - GlobeNewsWire

Syneos Health Leaders Recognized by HBA

Healthcare Businesswomen's Association Spotlights Kasey Boynton and Feni Komline for Biopharma Industry Impact Healthcare Businesswomen's Association Spotlights Kasey Boynton and Feni Komline for Biopha...

4 months ago - GlobeNewsWire

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

5 months ago - Zacks Investment Research

Syneos Health Shares Jump On Better Than Expected Q1 Earnings, FY22 Outlook

Syneos Health Inc's (NASDAQ: SYNH) Q1 revenue increased 10.5% on a reported basis and 11.7% on a constant currency (CC) basis to $1.34 billion, beating the consensus of $1.32 billion. Clinical Solutions...

5 months ago - Benzinga

Syneos Health (SYNH) Q1 Earnings and Revenues Top Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 5.21% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Syneos Health Names Michelle Keefe as Next Chief Executive Officer

Alistair Macdonald to Retire After 20 Years in Variety of Leadership Roles

5 months ago - GlobeNewsWire

Syneos Health Reports First Quarter 2022 Results

Highlights

5 months ago - GlobeNewsWire

Syneos Health Promotes Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to Executive Vice Pr...

MORRISVILLE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the promotions of two senior inter...

5 months ago - GlobeNewsWire

Syneos Health Schedules First Quarter 2022 Earnings Call for Friday, April 29th, 2022

MORRISVILLE, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will ...

5 months ago - GlobeNewsWire

Should Value Investors Pick Syneos Health (SYNH) Stock Now?

Let's see if Syneos Health, Inc. (SYNH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

6 months ago - Zacks Investment Research

Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe

Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

6 months ago - Zacks Investment Research

Here's Why You Should Retain Syneos Health (SYNH) For Now

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.

6 months ago - Zacks Investment Research

4 Stocks in Spotlight With AI Making Inroads in MedTech

MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.

Other symbols: MDRXMDTSYK
6 months ago - Zacks Investment Research

Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down

Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.

7 months ago - Zacks Investment Research

Syneos Health (SYNH) Q4 Earnings Beat Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 3.50% and 2.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research